Clinical Trial Update: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating on neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enoblituzumab (enoblituzumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING